恩度联合化疗治疗非小细胞肺癌临床观察

目的评价恩度(重组人血管内皮抑素,endostar,YH-16)联合NP(长春瑞宾+顺铂)或GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法 65例晚期NSCLC患者随机分为两组,试验组(36例)应用恩度联合NP或GP方案,对照组(29例)予常规NP或GP方案化疗。至少完成2个周期。结果试验组36例,有效率(RR)为33.3%,临床获益率(CBR)为75.0%;对照组29例,有效率(RR)24.1%,临床获益率(CBR)为58.6%。两组毒副反应相似,主要毒副反应主要有白细胞减少、恶心、呕吐等。结论恩度联合NP或GP方案治疗晚期NSCLC是一种安全、有效的方案。

Clinical Observation of Non-small Cell Lung Cancer Treated with YH-16 Combined with Chemotherapy

Objective To evaluate the efficacy and security of combined endostar injection with NP or GP regimen for the treatment of advanced non-small cell lung cancer（NSCLC）.Methods 40cases with advanced non-small cell lung caneer were divided into two groups,20 patients of trial group were treated with combination of endostar and NP/GP regimen,and 20 patients of control group only received NP/GP regimen.The efficacy and toxicity were evaluated after 2 cycles.Results The trial group＇s efficiency rate was 33.3% while the control group was 24.1%.The clinical benefit rate was 75.0% in the trial group and 58.6% in the control group.Side effects were neutropenia,nausea and vomiting.Conclusions The combination of YH-16 with NP/GP regimen can improve the efficacy rate of NSCLC obviously.In addition,side effect is no more than that of others.